HENDERSON, Nev., Nov. 6, 2023
/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)
("Volition"), a multi-national epigenetics company, and Veterinary
Pathology Group (VPG), a leading high quality diagnostic
laboratory, have joined forces to launch the Nu.Q® Vet Cancer
Test to veterinary practices in the UK and Ireland.
VPG is the first-to-market diagnostic laboratory in the UK and
Ireland to offer the
Nu.Q® Vet Cancer Test, a groundbreaking tool for the early
detection and monitoring of cancer in dogs.
Volition's Nu.Q® Vet Cancer Test is an accessible and
affordable screening tool for dogs with increased risk of
developing cancer, such as older dogs, certain breeds with higher
cancer prevalence rates and those dogs with familial history.
Dr Tom Butera, Chief Executive
Officer, Volition Veterinary Diagnostics Development LLP, said:
"Working with VPG, we are thrilled to be rolling out the
Nu.Q® Vet Cancer Test to veterinary practices across the UK
and Ireland, two renowned
pet-loving nations. It is a simple, non-invasive blood test that
can easily integrate into preventive care plans. Veterinarians can
run the test alongside routine blood work and imaging, to help
provide earlier cancer detection, improve a dog's quality of life
and give a better chance of effective treatment."
Fiona Gosling, Chief Executive
Officer at VPG, said: "Our collaboration with Volition highlights
the commitment of both organisations to improving the quality of
life for pets and supporting veterinary professionals in their
mission to provide the best possible care.
"By integrating the revolutionary Nu.Q® Vet Cancer Test into our
diagnostic portfolio, we are expanding our wellness testing
offering and empowering veterinarians with an accessible, cutting
edge tool to detect cancer in its early stages, ultimately leading
to better outcomes and improved patient care.
"Veterinary practices interested in offering the Nu.Q® Vet
Cancer Test to their clients can find out more at thevpg.co.uk or
visit us at stand K11 at the London Vet Show later this month."
Note:
1. There are approximately 11 million dogs as pets in
the UK, with 29% of households owning a dog. PDSA Paw Report
2023.
About VPG:
VPG are veterinary laboratory diagnostic experts, using
scientific excellence, innovation and personalised support to help
veterinary practices by delivering Excellence Everywhere. With over
20 years of experience and data, their vision is to set the
standard for the Veterinary industry, improving outcomes for
animals, pet owners, and their veterinary partners.
By supporting and investing in a team of exceptional people,
they aim to provide the best possible advice and care for their
clients, with the healthcare of animals at the forefront of
everything they do. VPG offer a comprehensive and extensive range
of tests as well as diagnostic advice for domestic pets, horses and
exotic species. Find the answers at thevpg.co.uk.
About Volition
Volition is a multi-national epigenetics company powered by
Nu.Q®, its proprietary nucleosome quantification platform. Through
its subsidiaries, Volition is developing simple, easy to use, cost
effective blood tests to help diagnose and monitor a range of
life-altering diseases in humans and animals including some cancers
and diseases associated with NETosis such as sepsis and COVID-19.
Early diagnosis and monitoring have the potential to not only
prolong the life of patients but also improve their quality of
life. The tests are based on the science of Nucleosomics™, which is
the practice of identifying and measuring nucleosomes in the
bloodstream or other bodily fluid - an indication that disease is
present.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore. For more details go to
www.volition.com.
The contents found at the Volition, VPG and PDSA website
addresses are not incorporated by reference into this document and
should not be considered part of this document. The website
addresses are included in this document as inactive textual
references only.
Media Enquiries:
Louise
Batchelor/Debra Daglish,
Volition, mediarelations@volition.com, +44 (0)7557 774620
Catrin Thomas, VPG Group,
catrin.thomas@thevpg.co.uk, +44 (0)7435 983344
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's expectations related to the
timing and launch of product sales, and the potential uses,
benefits and effectiveness of its Nucleosomics™ technology
platform, including the Nu.Q® Vet Cancer Test. Volition's actual
results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including, without limitation, results of studies testing the
efficacy of its tests, a failure by the marketplace to accept
Volition's, Nu.Q® Vet Cancer Test or other products based on its
Nucleosomics™ platform; Volition's failure to secure adequate
intellectual property protection; Volition's failure to obtain
necessary regulatory clearances or approvals to distribute and
market future products; Volition will face fierce competition and
its intended products may become obsolete due to the highly
competitive nature of the diagnostics and disease monitoring
markets and their rapid technological change; downturns in domestic
and foreign economies; and other risks, including those identified
in Volition's most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as other documents that Volition
files with the Securities and Exchange Commission. For instance, if
Volition fails to develop and commercialize diagnostic, prognostic
or disease monitoring products, it may be unable to execute its
plan of operations. Forward-looking statements are based on current
expectations, estimates and projections about Volition's business
based, in part, on assumptions made by management. These statements
are not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
View original
content:https://www.prnewswire.com/news-releases/volition-and-vpg-launch-nuq-vet-cancer-test-in-uk--ireland-301978421.html
SOURCE VolitionRx Limited